Physician profile
James A Blake
NPI 1073692414
$2,325.89
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,015 · 2020: $311.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $380.57 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $242.44 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.26 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $182.24 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $158.00 | 2019-2020 | |
| Novo Nordisk INC | $154.54 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $148.81 | 2019-2020 | |
| Amarin Pharma, INC. | $115.08 | 2019 | |
| Abbott Laboratories | $110.99 | 2019 | |
| Edwards Lifesciences Corporation | $101.29 | 2019-2020 | |
| Amgen INC. | $92.17 | 2019 | |
| Pfizer INC. | $88.26 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $75.48 | 2019 | |
| Boston Scientific Corporation | $58.73 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $57.53 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $48.45 | 2019 | |
| Biotronik INC. | $40.22 | 2019 | |
| Lilly USA, LLC | $39.88 | 2019 | |
| Astellas Pharma US INC | $24.09 | 2019 | |
| Daiichi Sankyo INC. | $18.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.